Robert McLeay is the founder of medical startup company, DoseMe, the first company in the world to offer precision drug dosing software specifically developed for clinical use. Prior to this, he led software development teams and then completed a PhD in Bioinformatics at UQ’s Institute of Molecular Bioscience.
Today, DoseMeRx enables individualised dosing in hundreds of hospitals across 10 countries, supporting over 7,000 clinician users. It supports 42 drug models ranging from antibiotics to transplant medicines to chemotherapy, and to date has calculated over 1.4 million medication doses.
